報價延遲最少15分鐘:2025/05/31 11:58 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.729 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.42/-0.82
|
|
企業價值
4.67M
|
| 資產負債 |
|
每股賬面淨值
1.14
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 11:58 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase3 data from its STAR-1 clinical trial in March 2025. |